Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patientsPRNewsWire • 04/08/21
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitisPRNewsWire • 04/06/21
Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or RearrangementBusiness Wire • 03/29/21
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer ChemotherapyBusiness Wire • 03/23/21
Incyte's Jakafi failed Phase 3 clinical trial as a treatment for some severely ill COVID-19 patientsMarket Watch • 03/19/21
Incyte's Ruxolitinib Fails To Beat Placebo In Improving Mortality In Critically-Ill COVID-19 PatientsBenzinga • 03/19/21
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical VentilationBusiness Wire • 03/18/21
Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021Business Wire • 03/11/21
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) TrialPRNewsWire • 03/03/21
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)Business Wire • 02/26/21
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host DiseaseBusiness Wire • 02/22/21
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic DermatitisBusiness Wire • 02/19/21
Barrick, Lyft, Nordstrom, Twitter and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 02/10/21
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/09/21
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical ProgramsBusiness Wire • 02/09/21